At present, the medical treatment of CHI is limited to diazoxide as first line and synthetic somatostatin receptor ligands (SRLs) as second line options
It is not a marketing authorisation of GHRP-2 as a therapy, nor a clearance for use beyond diagnosis
Think of it like this: Ipamorelin is the spark, CJC-1295 is the rhythm, and Tesamorelin is the fat-scorching turbo
Like, candidly, there it isn't about quality of care
Pompella et al, 2003 describe a number of signalling cascades affected by protein S-glutathionylation: NF-kB/p50 (Pineda-Molina et al., 2001) and PTP1B phosphatase (Barrett et al., 1999), for example, which are able to affect cell proliferation
Additional Information How to cite this article : Li, J.-M